Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST) Tate CW, et. al. Journal of Cardiac Failure, 2007
A Polymorphism Within a Conserved β1-adrenergic Receptor Motif Alters Cardiac Function and β-blocker Response in Human Heart Failure Liggett S, et. al. The National Academy of Sciences, 2006
Impact of Nonfatal Myocardial Infarction on Outcomes in Patients With Advanced Heart Failure and the Effect of Bucindolol Therapy O’Connor C, et. al. The American Journal of Cardiology, 2005
Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the Beta-Blocker Evaluation of Survival Trial (BEST) Bristow M, et. al. Circulation, 2004
β1 – Adrenergic Receptor Polymorphisms Confer Differential Function and Predisposition to Heart Failure Mialet Perez, et. al. Nature Medicine, 2003
A Comparative Analysis of the Results from 4 Trials of β-Blocker Therapy for Heart Failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS Domanski M, et. al. Journal of Cardiac Failure, 2003
The Effect of Diabetes on Outcomes of Patients With Advanced Heart Failure in the BEST Trial Domanski M, et. al. Journal of the American College of Cardiology, 2003
Synergistic Polymorphisms of β1 and α2c – Adrenergic Receptors and the Risk of Congestive Heart Failure Small, et. al. New England Journal of Medicine, 2002
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure The BEST Manuscript Writing Committee New England Journal of Medicine, 2001
ACC 2008
ARCA biopharma will be attending ACC’s 57th Annual Scientific Session in Chicago on March 29 – April 1, 2008. For more information on ARCA biopharma, stop by booth #26064
